TriangleNCT00509665 · OUTCOME
Number of Patients Who Had Greater Than Grade 2 Toxicity
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- from time of initial treatment until end of study, an average of 6 months
Analysis population: Patients who were treated on study and had greater than grade 2 toxicity.
Groups in this outcome
Gemcitabine+Doxorubicin
doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle. gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
| Group | Source count |
|---|---|
| Gemcitabine+Doxorubicin | 18 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Gemcitabine+Doxorubicin | 10 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 10
- denoms
- counts
- group Id
- OG000
- value
- 18
- units
- Participants
- groups
- description
- doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle. gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
- id
- OG000
- title
- Gemcitabine+Doxorubicin
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Patients who were treated on study and had greater than grade 2 toxicity.
- reporting Status
- POSTED
- time Frame
- from time of initial treatment until end of study, an average of 6 months
- title
- Number of Patients Who Had Greater Than Grade 2 Toxicity
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice